Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence
Status:
Recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
In this study, participants with histologically diagnosed locally advanced esophageal
squamous cell carcinoma who have received preoperative cisplatin-based chemoradiotherapy
followed by surgery harbouring high risk of tumor recurrence will receive adjuvant
cisplatin-based chemoradiotherapy followed by pembrolizumab. The primary study hypothesis is
that adjuvant pembrolizumab will improve the 1-year recurrence-free survival rate compared to
historical control.